What we do
HQ & Pipeline
Digital Therapeutics
Annual and Sustainability Report 2022
- Advancing in a challenging environment
- amorphOX® - World-leading technology enabling new development projects
- Digital therapies will increase access to qualified psychosocial support
- Commercial presence in the US and a growing product portfolio
Key News
MARCH 15, 2023
New date for publication of the Annual Report 2022 is March 28
MARCH 15, 2023
Notice Annual General Meeting
FEBRUARY 3, 2023
NDA submitted with the FDA for OX124 a highdose medication for opioid overdose
Listed on Nasdaq Stockholm´s mainlist
Orexo is listed on Nasdaq Stockholm´s main list and can also be traded in the US at the OTCQX Market.
News Flow
Press Releases & News
Orexo postpones publication of the Annual Report
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Invitation to presentation of Orexo´s Interim Report Q4 2022 incl. Full Year Report
Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
Orexo Social
@OrexoABpubl
22 March 2023
PARTNERSHIPS ARE KEY FOR OUR SUCCESS. This week we are glad to have our business development team, represented by P… https://t.co/06ijNODUkb
@OrexoABpubl
16 March 2023
March 28 is the new date for publication of our Annual Report for 2022, also incl our Sustainability Report. Earli… https://t.co/4Q5X1Vr0jr
@OrexoABpubl
13 March 2023
Brief interview with CEO Nikolaj Sørensen, conducted at the Stockholm Corporate Finance Life Science Seminar last w… https://t.co/glFZPUDR1r
Financial Snapshot
Group net revenues
624 MSEK
LTM1
Group EBITDA
-115 MSEK
LTM1
US Pharma segment EBIT
308 MSEK
LTM1
Cash position
352 MSEK
Q4 2022
1 Last Twelve Months, Q122-Q422, for more information about financial development Link